Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Assets (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-Current Assets for 15 consecutive years, with $45.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 13.94% to $45.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.8 million through Dec 2025, down 13.94% year-over-year, with the annual reading at $45.0 million for FY2025, 19.94% down from the prior year.
  • Non-Current Assets for Q4 2025 was $45.8 million at Aytu Biopharma, up from $43.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $160.4 million in Q2 2021, with the low at $43.9 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $74.5 million, with a median of $62.3 million recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 106.03% in 2021, then plummeted 51.57% in 2022.
  • Over 5 years, Non-Current Assets stood at $136.3 million in 2021, then crashed by 48.03% to $70.8 million in 2022, then dropped by 15.46% to $59.9 million in 2023, then dropped by 11.2% to $53.2 million in 2024, then dropped by 13.94% to $45.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $45.8 million, $43.9 million, and $45.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.